A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

Figure 4 A: Response rate relative to baseline (increase of ≥ 1 CSBM per week) by week (ITT population); B: Absolute response rate (increase of ≥ 3 CSBM per week) (ITT population). ^aP < 0.05 vs placebo; Mean number of CSBMs per week at baseline: tegaserod 0.36; placebo 0.31.